Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 120

Next Previous
Drug Profile

CT 120

Alternative Names: Anti CD19 CD22 CAR T-cell therapy - IASO Biotherapeutics; Anti-CD19/CD22 CAR T-cell therapy - IASO Biotherapeutics; Anti-CD19XCD22 bispecific chimeric antigen receptor (CAR) T cells - IASO Biotherapeutics; CT-120

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing IASO Biotherapeutics
  • Developer Nanjing IASO Biotherapeutics; Tongji Hospital
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-0 development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in China (Parenteral)
  • 10 May 2022 Adverse events and pharmacodynamic data in relapsed/refractory (R/R) CD19+ B-cell non-Hodgkin lymphomas (B-NHL) and acute lymphoblastic leukemias (B-ALL) released by Nanjing IASO Biotherapeutics
  • 25 Nov 2021 Investigation in Non-Hodgkin's lymphoma in USA (Parenteral) as of November 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top